Aficamten Raised a Quality-of-Life Score 4 Points Over Placebo in Non-Obstructive Hypertrophic Cardiomyopathy as Cytokinetics Readies FDA Filing
New company-reported analyses suggest aficamten modestly improved quality of life and heart structure in non-obstructive hypertrophic cardiomyopathy, but the drug is not yet approved for this use.
Medical Daily ·